Teneligliptin is an oral antidiabetic drug that belongs to the DPP-4 (dipeptidyl peptidase-4) inhibitor class. It helps manage type 2 diabetes mellitus (T2DM) by increasing the levels of incretin hormones (GLP-1 and GIP), which in turn enhance insulin secretion and suppress glucagon release in a glucose-dependent manner. This leads to improved glycemic control without a significant risk of hypoglycemia.
Teneligliptin is often used alone or in combination with other antidiabetic agents like metformin, sulfonylureas, or SGLT2 inhibitors.
Indications include:
∙ Type 2 diabetes mellitus (as monotherapy or add-on therapy)
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Parent: Teneligliptin
Impurities in teneligliptin arise from its multi-step chemical synthesis, including thiazolidine ring formation, piperazine coupling, and quinoline derivative incorporation, as well as from degradation under stress conditions such as oxidation or hydrolysis. As a long-term oral medication, impurity control must follow ICH Q3A/B, USP, and EP standards.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Teneligliptin is used to manage type 2 diabetes mellitus by improving blood glucose control, especially in patients with inadequate control on diet and exercise alone or with other antidiabetic agents.
It inhibits DPP-4, increasing GLP-1 and GIP levels, which enhance glucose-dependent insulin secretion and suppress glucagon, lowering postprandial and fasting glucose.
It may be used with dose adjustments or caution, depending on severity. Unlike some other DPP-4 inhibitors, teneligliptin has a mixed hepatic and renal route of elimination.
Yes, but it should be stored in a cool, dry place, protected from light and moisture, as it may degrade under acidic, basic, or oxidative conditions.
